Evolution of resistance to thyroid cancer therapy | Zendy

Carmelo Nucera | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Evolution of resistance to thyroid cancer therapy

Author(s) -

Carmelo Nucera

Publication year - 2016

Publication title -

aging

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.473

H-Index - 90

ISSN - 1945-4589

DOI - 10.18632/aging.101030

Subject(s) - thyroid cancer , resistance (ecology) , medicine , cancer , oncology , biology , ecology

The prognosis of differentiated thyroid carcinoma (DTC), of which the majority are papillary thyroid carcinoma (PTC), shows clinical diversity among patients related to age, tumor histology and size, extra-thyroidal extension, metastasis, and thyroid follicular cell avidity for iodide. First-line preferred treatment for DTC is thyroid surgery, whenever possible, followed by radioactive iodine (RAI) in selected patients, and levothyroxine therapy in all patients (Haugen and Sherman, 2013; PMID: 23575762). As for all cancers, a percentage of patients with DTC fail to respond or respond very poorly to targeted therapies (primary resistance). In addition, many tumors that initially respond to therapy become resistant within months or even weeks (secondary resistance).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research